Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gynecology

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757627

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757627

Gynecology Drugs

PUBLISHED:
PAGES: 386 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Gynecology Drugs Market to Reach US$8.1 Billion by 2030

The global market for Gynecology Drugs estimated at US$6.0 Billion in the year 2024, is expected to reach US$8.1 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Non-Hormonal Therapy, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Hormonal Therapy segment is estimated at 7.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 8.2% CAGR

The Gynecology Drugs market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global "Gynecology Drugs" Market - Key Trends & Drivers Summarized

Why Are Gynecology Drugs Becoming Central to Women’s Health Management?

Gynecology drugs are a fundamental part of the healthcare landscape, addressing a broad spectrum of conditions specific to women’s reproductive health-from menstrual disorders, hormonal imbalances, and endometriosis to infertility, menopause symptoms, and gynecological infections. As awareness surrounding women’s health issues continues to grow globally, more patients are actively seeking medical intervention for concerns that were previously stigmatized or undertreated. This cultural shift, along with increasing healthcare access, is driving demand for targeted pharmaceutical solutions. The expansion of gynecology-focused clinics and integration of women’s health into primary care pathways are contributing to earlier diagnosis and more consistent treatment across age groups and geographies.

How Is Innovation Reshaping Therapeutic Options for Gynecological Conditions?

The gynecology drugs market is evolving rapidly with the development of more effective, better-tolerated, and personalized therapeutic options. Hormone replacement therapies (HRT), selective estrogen receptor modulators (SERMs), and oral contraceptives are being reformulated with improved safety profiles and convenience-focused delivery methods, such as extended-release tablets, vaginal rings, and injectables. Non-hormonal drugs for conditions like menopause and endometriosis are gaining popularity among women seeking alternatives due to side effect concerns. Meanwhile, targeted biologics and immunotherapies are being explored for gynecologic cancers and chronic pelvic inflammatory diseases. The integration of digital health tools-like menstrual tracking apps linked to treatment adherence and remote monitoring-is further improving care outcomes and compliance.

Where Is Market Demand Accelerating and Who Are the Key Stakeholders?

North America dominates the gynecology drugs market, largely due to robust healthcare infrastructure, high diagnostic rates, and the presence of major pharmaceutical innovators. Europe follows closely, with strong demand in Western nations supported by national health programs and a rising focus on women-specific care initiatives. In Asia-Pacific, markets such as India, China, and Japan are witnessing increasing demand, fueled by urbanization, growing middle-class access to healthcare, and greater attention to maternal and reproductive health. Pharmaceutical companies, gynecologists, general practitioners, and women’s health advocacy groups are all key stakeholders in this expanding market. Additionally, the rise of telemedicine and online pharmacies is improving drug accessibility and reducing barriers to treatment in underserved regions.

What Factors Are Powering the Growth of the Gynecology Drugs Market?

The growth in the gynecology drugs market is driven by several factors, including increased awareness of women’s health issues, expanded access to diagnostic and treatment facilities, and a growing portfolio of targeted therapies for reproductive and hormonal conditions. Technological advances in drug delivery systems, the introduction of novel therapeutics for underserved indications such as uterine fibroids and polycystic ovary syndrome (PCOS), and rising demand for fertility treatments are further fueling the market. Additionally, pharmaceutical R&D investments in oncology for gynecological cancers, along with favorable regulatory support and insurance coverage for hormonal therapies and birth control, are contributing to sustained market expansion. These dynamics are transforming gynecology drugs into a key growth segment within the broader pharmaceutical industry.

SCOPE OF STUDY:

The report analyzes the Gynecology Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapeutics (Non-Hormonal Therapy, Hormonal Therapy); Indication (Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication, Other Indications); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Besins Healthcare
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cipla Limited
  • Eli Lilly and Company
  • Emcure Pharmaceuticals
  • Ferring Pharmaceuticals
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Gedeon Richter Plc
  • Hetero Labs Limited
  • Johnson & Johnson
  • Lupin Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Organon & Co.
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP37039

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Gynecology Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of PCOS, Endometriosis, and Hormonal Disorders Drives Demand for Specialized Gynecology Drugs
    • Advances in Reproductive Health Treatments Strengthen Business Case for Targeted Gynecology Therapies
    • Increased Awareness of Womens Health Throws Spotlight on Early Diagnosis and Treatment Uptake
    • Expanding Access to Fertility Treatments and IVF Fuels Demand for Hormonal and Ovulation-Stimulating Drugs
    • Government and NGO-Led Awareness Campaigns Sustain Growth in Contraceptive and Preventive Therapies
    • Innovation in Hormone Replacement and Menopause Management Drives Market Differentiation
    • Regulatory Approvals and Pipeline Growth in Rare Gynecologic Conditions Expand Therapeutic Scope
    • Rise of Telehealth in Womens Health Enhances Accessibility to Prescription and OTC Treatments
    • Shift Toward Personalized Medicine in Gynecology Accelerates Use of Genomic and Targeted Drugs
    • Increased Investment in Endometriosis and Uterine Fibroid Research Propels Product Innovation
    • Consumer Demand for Non-Invasive and Oral Alternatives Supports Development of Novel Formulations
    • Integration of Gynecology Drug Portfolios by Big Pharma Strengthens Global Distribution Reach
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Gynecology Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Gynecology Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Gynecology Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Gynecology Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Non-Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Non-Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Non-Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Contraception Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Contraception Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Contraception Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Female Infertility Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Female Infertility Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Female Infertility Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Postmenopausal Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Postmenopausal Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Postmenopausal Disorders Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Polycystic Ovary Syndrome Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Polycystic Ovary Syndrome Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Polycystic Ovary Syndrome Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Osteoporosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Osteoporosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Osteoporosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Endometriosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Endometriosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Endometriosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • JAPAN
    • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • CHINA
    • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • EUROPE
    • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Gynecology Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Gynecology Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Gynecology Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • FRANCE
    • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • GERMANY
    • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Gynecology Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Gynecology Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Gynecology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • INDIA
    • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Gynecology Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Gynecology Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Gynecology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Gynecology Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Gynecology Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Gynecology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
  • AFRICA
    • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!